Merck KGaA Agrees to Lower Prices for IVF Medications in U.S. Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2025
0mins
Source: NASDAQ.COM
Agreement for IVF Access: Merck KGaA's U.S. division, EMD Serono, has partnered with the Trump administration to enhance access to IVF therapies for over 10 million American women, offering significant discounts on treatments through the TrumpRx.gov platform starting January 2026.
Regulatory and Investment Initiatives: EMD Serono will be exempt from Section 232 tariffs on its products in exchange for investing in U.S. biopharmaceutical manufacturing, and it plans to expedite the review of its drug Pergoveris under the FDA's National Priority Voucher program to improve fertility treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
